Division of Medical Oncology, National Cancer Centre Singapore , Singapore, Singapore.
Expert Opin Biol Ther. 2020 Jul;20(7):687-693. doi: 10.1080/14712598.2020.1749593. Epub 2020 Apr 20.
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide and up to recently, sorafenib was the only approved systemic treatment options. In recent years, many other treatment options have received approval for advanced HCC, including nivolumab, a Programmed-Death-1 (PD-1) inhibitor.
We review the current treatment landscape of HCC, an overview of the characteristics of nivolumab and current ongoing and completed trials of nivolumab.
Nivolumab is generally well tolerated and has modest single-agent activity as a monotherapy in advanced HCC. Further studies are required to better explore its role as part of combination approaches, in adjuvant/neoadjuvant setting, as well as to understand the impact of sequencing of its use with other systemic therapy options.
肝细胞癌（HCC）是全球癌症相关死亡的主要原因之一，直到最近，索拉非尼仍是唯一获得批准的系统治疗方案。近年来，许多其他治疗方案已被批准用于晚期 HCC，包括 nivolumab，一种程序性死亡受体-1（PD-1）抑制剂。
我们回顾了 HCC 的当前治疗现状，概述了 nivolumab 的特征以及正在进行和已完成的 nivolumab 临床试验。
nivolumab 通常具有良好的耐受性，作为单一药物在晚期 HCC 中的活性适度。需要进一步的研究来更好地探索其作为联合治疗方案的一部分、辅助/新辅助治疗中的作用，以及了解其与其他系统治疗方案联合使用的顺序的影响。
